Latin American association for the study of the liver recommendations on treatment of hepatitis C

Annals of Hepatology

Volumn 13, Issue , 2014, Pages s1-s66

  Méndez Sánchez, Nahum ^a   Paraná, Raymundo ^b   Cheinquer, Hugo ^c   de Mattos, Angelo Alves ^d   Gadano, Adrian ^e   Silva, Marcelo ^f   Pessôa, Mario G ^g   Gomes Ferraz, Maria L ^h   Soza, Alejandro ⁱ   Cassia Mendes Correa, M ^g   Chávez Tapia, Norberto C ^a   Dagher, Lucy ^j   Padilla, Martín ^k   Hernandez, Nelia ^l   Sánchez Avila, Juan F ^m   Contreras, Fernando ⁿ   Moraes Coelho, Henrique S ^o   Parise, Edison R ^h   Bessone, Fernando ^p   Uribe, Misael ^a  

^a LIVER RESEARCH UNIT   (Mexico)

^b FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^c FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^d UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

^e HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^f UNIVERSIDAD AUSTRAL   (Argentina)

^g UNIVERSITY OF SÃO PAULO   (Brazil)

^h FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

ⁱ PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^j Metropolitan Policlinic   (Venezuela)

^k HOSPITAL NACIONAL GUILLERMO ALMENARA IRIGOYEN   (Peru)

^l Guillermo Almenara National Hospital ^*  (Uruguay)

^m INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

ⁿ Universidad Nacional Pedro Henriquez Urena   (Dominican Republic)

^o FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^p UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

more..

Author keywords

Direct acting antiviral; Hepatitis C; Pegylated interferon; Ribavarin

Indexed keywords

ABT 450; ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; ASUNAPREVIR; BILIRUBIN; BOCEPREVIR; DACLATASVIR; DASABUVIR; FALDAPREVIR; GS 5816; LEDIPASVIR; MK 4782; NONSTRUCTURAL PROTEIN 2; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; NONSTRUCTURAL PROTEIN 4B; NONSTRUCTURAL PROTEIN 5B; OMBITASVIR; PEGINTERFERON; PLACEBO; RIBAVIRIN; RITONAVIR; SERINE PROTEINASE INHIBITOR; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANIPREVIR; VIRUS RNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAL COMPLAINT; ANEMIA; ANTIVIRAL RESISTANCE; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD ANALYSIS; BLOOD TRANSFUSION; BODY PIERCING; CLINICAL TRIAL (TOPIC); DISEASE CLASSIFICATION; DISEASE SURVEILLANCE; DRUG ABUSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FATALITY; DRUG METABOLISM; DRUG SAFETY; DRUG TARGETING; DYSGEUSIA; ELASTOGRAPH; ELASTOGRAPHY; ENVIRONMENTAL EXPOSURE; FATIGUE; FOOD DRUG INTERACTION; HEADACHE; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HEALTH INSURANCE; HEMODIALYSIS; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INSOMNIA; INTERNATIONAL NORMALIZED RATIO; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIPID DIET; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FUNCTION TEST; LIVER FUNCTION TEST KIT; LIVER TRANSPLANTATION; MEDICAL DECISION MAKING; MIXED INFECTION; NAUSEA; NEEDLESTICK INJURY; NEUTROPHIL COUNT; ORGAN TRANSPLANTATION; PATIENT SELECTION; PERSONAL HYGIENE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PREVALENCE; PROGNOSIS; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECOMMENDED DRUG DOSE; RISK ASSESSMENT; SEXUAL BEHAVIOR; SIDE EFFECT; SOUTH AND CENTRAL AMERICA; SYSTEMATIC REVIEW (TOPIC); TATTOOING; THROMBOCYTE COUNT; TREATMENT DURATION; UNPROTECTED SEX; UNSPECIFIED SIDE EFFECT; VIRAL CLEARANCE; VIRUS TRANSMISSION; ADVERSE EVENT; CHRONIC HEPATITIS C; COMBINATION DRUG THERAPY; CONSENSUS; DRUG EFFECT; DRUG INTERACTION; HEPACIVIRUS; PATHOGENICITY; RECURRENT DISEASE; RISK FACTOR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VIRUS ACTIVATION;

ANTIVIRAL AGENTS; COINFECTION; CONSENSUS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS B; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LATIN AMERICA; LIVER TRANSPLANTATION; RECURRENCE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VIRUS ACTIVATION;

EID: 84907524464     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)30920-2     Document Type: Article

References (315)

1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333-42.
2. WHO. Guidelines for the screening, care and treatment of persons with hepatitis C infection. April 2014, accessed by http://www. who. int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/.
3. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012; 156: 271-8.
4. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
5. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
6. Andriulli A, Mangia A, Iacobellis A, Ippolito A, Leandro G, Zeuzem S. Metaanalysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Aliment Pharmacol Ther 2008; 28: 397-404.
7. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, et al. SPRINT-2 investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.
8. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, et al. ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
9. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, et al. HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-17.
10. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, et al. REALIZE Study Team. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-28.
11. Chávez-Tapia NC, Ridruejo E, Alves de Mattos A, Bessone F, Daruich J, Sánchez-Ávila JF, Cheinquer H, et al. Latin American Association for the Study of the Liver. Ann Hepatol 2013; 12 (Suppl 2): s3-35.
12. Halfon P, Locarnini S. Hepatitis C virus resistance to protease inhibitors. J Hepatol 2011; 55: 192-206.
13. Berger KL, Triki I, Cartier M, Marquis M, Massariol MJ, Böcher WO, Datsenko Y, et al. Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir. Antimicrob Agents Chemother 2014; 58: 698-705.
14. Fried MW, Buti M, Dore GJ, Flisiak R, Ferenci P, Jacobson I, Marcellin P, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 2013; 58: 1918-29.
15. Wang C, Huang H, Valera L, Sun JH, O'Boyle DR 2nd, Nower PT, Jia L, et al. Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052. Antimicrob Agents Chemother 2012; 56: 1350-8.
16. Lam AM, Espiritu C, Bansal S, Micolochick Steuer HM, Niu C, Zennou V, Keilman M, et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother 2012; 56: 3359-68.
17. Viral Hepatitis Global Policy. World Hepatitis Alliance; 2010.
18. Gidding HF, Amin J, Dore GJ, Ward K, Law MG. Hospitalrelated morbidity in people notified with hepatitis C: a population-based record linkage study in New South Wales, Australia. J Hepatol 2010; 53: 43-9.
19. Duberg AS, Pettersson H, Aleman S, Blaxhult A, Daviðsdóttir L, Hultcrantz R, Bäck E, et al. The burden of hepatitis C in Sweden: a national study of inpatient care. J Viral Hepatol 2011; 18: 106-18.
20. Myers RP, Liu M, Shaheen AAM. The burden of hepatitis C virus infection is growing: A Canadian population-based study of hospitalizations from 1994 to 2004. Can J Gastroenterol 2008; 22: 381-87.
21. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29(Suppl 1): S74-81.
22. Lauer GM, Walker BD. Hepatitis C Virus Infection. N Engl J Med 2001; 345: 41-52.
23. Younossi ZM, Kanwal F, Saab S, et al. The impact of hepatitis C burden: an evidence-based approach. Aliment Pharmacol Ther 2014; 39: 518-31.
24. Mathurin P. HCV burden in Europe and the possible impact of current treatment. Dig Liver Dis 2013; 30: (45 Suppl 5): S314-7.
25. Kershenobich D, Razavi HA, Sánchez-Avila JF, Bessone F, Coelho HS, Dagher L, Gonçales FL, et al. Trends and projections of hepatitis C virus epidemiology in Latin America. Liver Int 2011; 31 (Suppl 2): S18-29.
26. Szabo SM, Bibby M, Yuan Y, Donato BM, Jiménez-Mendez R, Castañeda-Hernández G, Rodríguez-Torres M, et al. The epidemiologic burden of hepatitis C virus infection in Latin America. Ann Hepatol 2012; 11: 623-35.
27. Pereira LM, Martelli CM, Moreira RC, Merchan-Hamman E, Stein AT, Cardoso MR, Figueiredo GM, et al. Prevalence and risk factors of Hepatitis C virus infection in Brazil, 2005 through 2009: a cross-sectional study. BMC Infect Dis 2013; 13: 60.
28. Davis KL, Mitra D, Medjedovic J, Beam C, Rustgi V. Direct economic burden of chronic hepatitis C virus in a United States managed care population. J Clin Gastroenterol 2011; 45: 17-24.
29. Razavi H, Elkhoury AC, Elbasha E, Estes C, Pasini K, Poynard T, Kumar R. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology 2013; 57: 2164-70.
30. Ward JW. The epidemiology of chronic hepatitis C and one-time hepatitis C virus testing of persons born during 1945 to 1965 in the United States. Clin Liver Dis 2013; 17: 1-11.
31. Schmidt AJ, Falcato L, Zahno B, Burri A, Regenass S, Müllhaupt B, Bruggmann P. Prevalence of hepatitis C in a Swiss sample of men who have sex with men: whom to screen for HCV infection? BMC Public Health 2014; 14: 3.
32. Larney S, Kopinski H, Beckwith CG, Zaller ND, Jarlais DD, Hagan H, Rich JD. Incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis. Hepatology 2013; 58: 1215-24.
33. Bialek SR, Terrault NA. The changing epidemiology and natural history of hepatitis C virus infection. Clin Liver Dis 2006; 10: 697-715.
34. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infections and HCV-related chronic disease. MMWR Recomm Rep 1998; 47: 1-39.
35. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. U. S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA). MMWR Recomm Rep 1999; 48: 1-59.
36. Ferreira A de S, Perez R de M, Ferraz ML, Lewis-Ximenez LL, Pereira JL, de Almeida PR, de Mattos AA, et al. Acute hepatitis C in Brazil: results of a national survey. J Med Virol 2011; 83: 1738-43.
37. Tovo CV, Dos Santos DE, de Mattos AZ, de Almeida PR, de Mattos AA, Santos BR. Ambulatorial prevalence of hepatitis B and C markers in patients with human immunodeficiency virus infection in a general hospital. Arq Gastroenterol 2006; 43: 73-6.
38. Denniston MM, Klevens RM, McQuillan GM, Jiles RB. Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001-2008. Hepatology 2012; 55: 1652-61.
39. Jacobson IM, Davis GL, El-Serag H, Negro F, Trépo C. Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol 2010; 8: 924-33.
40. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138: 513-21.
41. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Ward JW. Hepatitis C virus testing of persons born during 1945-1965: recommendations from the Centers for Disease Control and Prevention. Ann Intern Med 2012; 157: 817-22.
42. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Teo CG, Jewett A, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012; 61: 1-32.
43. Mahajan R, Liu SJ, Klevens RM, Holmberg SD. Indications for testing among reported cases of HCV infection from enhanced hepatitis surveillance sites in the United States, 2004-2010. Am J Public Health 2013; 103: 1445-49.
44. Prati GM, Aghemo A, Rumi MG, D'Ambrosio R, De Nicola S, Donato MF, Degasperi E, et al. Hyporesponsiveness to PegIFN?2B plus ribavirin in patients with hepatitis C-related advanced fibrosis. J Hepatol 2012; 56: 341-7.
45. Williams MJ, Lang-Lenton M; Trent HCV Study Group. Progression of initially mild hepatic fibrosis in patients with chronic hepatitis C infection. J Viral Hepat 2011; 18: 17-22.
46. Sebastiani G, Alberti A. How far is noninvasive assessment of liver fibrosis from replacing liver biopsy in hepatitis C? J Viral Hepat 2012; 19 (Suppl 1): 18-32.
47. Gonzalez HC, Jafri SM, Gordon SC. Role of liver biopsy in the era of direct-acting antivirals. Curr Gastroenterol Rep 2013; 15(2): 307.
48. Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample the milder the disease. J Hepatol 2003; 39: 239-44.
49. Bhogal H, Sterling RK. Staging of liver disease-which option is right for my patient? Infect Dis Clin N Am 2012; 26: 849-6.
50. Berzigotti A, Castera L. Hepatology snapshot-update on ultrasound imaging of liver fibrosis. J Hepatol 2013; 58: 180-2.
51. Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, de Lédinghen V, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005; 41: 48-54.
52. Friedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, Zeuzem S, Herrmann E. Performance of transient elastography for the staging of liver fibrosis: a meta-Analysis. Gastroenterology 2008; 134: 960-74.
53. Vergniol J, Foucher J, Terrebonne E, Bernard PH, le Bail B, Merrouche W, Couzigou P, et al. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology 2011; 140: 1970-9.
54. Lucidarme D, Foucher J, Le Bail B, Vergniol J, Castera L, Duburque C, Forzy G, et al. Factors of accuracy of transient elastography (fibroscan) for the diagnosis of liver fibrosis in chronic hepatitis C. Hepatology 2009; 49: 1083-9.
55. Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B and C. Gastroenterology 2012; 142: 1293-300.
56. Bota S, Herkner H, Sporea I, Salzl P, Sirli R, Neghina AM, Peck-Radosavljevic M. Meta-analysis: ARFI elastography versus transient elastography for the evaluation of liver fibrosis. Liver Int 2013; 33: 1138-47.
57. Wang Q-B, Zhu H, Liu H-L, Zhang B. Performance of magnetic resonance elastography and diffusion-weighted imaging for the staging of hepatic fibrosis: a meta-analysis. Hepatology 2012; 56: 239-47.
58. Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, Darriet M, et al. Prospective comparison of transient elastography, FibroTest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-50.
59. Degos F, Perez P, Roche B, Mahmoudi A, Asselineau J, Voitot H, Bedossa P, et al. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol 2010; 53: 1013-21.
60. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.
61. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, Fontaine H, et aL. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection: comparison with liver biopsy and fibrotest. Hepatology 2007; 46: 32-6.
62. Sebastiani G, Halfon P, Castera L, Pol S, Thomas DL, Mangia A, Di Marco V, et al. SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology 2009; 49: 1821-7.
63. Boursier J, Vergniol J, Sawadogo A, Dakka T, Michalak S, Gallois Y, Le Tallec V, et al. The combination of a blood test and Fibroscan improves the non-invasive diagnosis of liver fibrosis. Liver Int 2009; 29: 1507-15.
64. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48: 835-47.
65. Boursier J, de Ledinghen V, Zarski JP, Rousselet MC, Sturm N, Foucher J, Leroy V, et al. A new combination of blood test and fibroscan for accurate non-invasive diag nosis of liver fibrosis stages in chronic hepatitis C. Am J Gastroenterol 2011; 106: 1255-63.
66. AASLD, IDSA, IAS-USA. Recommendations for testing, managing, and treating hepatitis C. http://www. hcvguidelines. org. (Accessed: 27/04/2014.).
67. EASL. Recommendations on treatment of hepatitis C. http://files. easl. eu/easl-recommendations-on-treatment-of-hepatitis-C/index. htm. (Accessed: 27/04/2014.).
68. Bruno S, Crosignani A, Facciotto C, Rossi S, Roffi L, Redaelli A, de Franchis R, et al. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology 2010; 51: 2069-76.
69. Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, Lee WM, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010; 52: 833-44.
70. Van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-93.
71. Lemoine M, Nayagam S, Thursz M. Viral hepatitis in resource-limited countries and access to antiviral therapies: current and future challenges. Future Virol 2013; 8: 371-380.
72. Sitole M, Silva M, Spooner L, Comee MK, Malloy M. Telaprevir versus boceprevir in chronic hepatitis C: a metaanalysis of data from phase II and III trials. Clin Ther 2013; 35: 190-7.
73. Cooper C, Lester R, Thorlund K, Druyts E, El Khoury AC, Yaya S, Mills EJ. Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis. QJM 2013; 106: 153-63.
74. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-24.
75. Buti M, Agarwal K, Horsmans Y, Sievert W, Janczewska E, Zeuzem S, Nyberg L, et al. Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C. Gastroenterology 2014; 146: 744-753.
76. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-87.
77. Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV, Moroz L, et al. Simeprevir with pegylated interferon alpha-2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014 Jun 3. [Epub ahead of print].
78. Manns M, Marcellin P, Poordad F, de Araujo ES. Simeprevir with pegylated interferon alpha-2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2014 Jun 3. [Epub ahead of print].
79. Alves R, Queiroz AT, Pessoa MG, da Silva EF, Mazo DF, Carrilho FJ, Carvalho-Filho RJ, et al. The presence of resistance mutations to protease and polymerase inhibitors in Hepatitis C virus sequences from the Los Alamos databank. J Viral Hepat 2013; 20: 414-21.
80. Forns X, Lawitz E, Zeuzem S, Gane E, Bronowicki JP, Andreone P, Horban A, et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: A phase 3 trial. Gastroenterology 2014; 146: 1669-79.
81. Izumi N, Hayashi N, Kumada H, Okanoue T, Tsubouchi H, Yatsuhashi H, Kato M, et al. Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies. J Gastroenterol 2014; 49: 941-53.
82. Sulkowski MS, Jacobson I, Ghalib R, et al. Once-daily simeprevir (TMC-435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV genotype-1 prior null responders with METAVIR F0-2: COSMOS study subgroup analysis. 49th Annual Meeting of EASL. London, UK, April 9-13, 2014.
83. Lawitz M, Ghalib R, Rodriguez-Torres M, et al. Simeprevir plus sofosbuvir with/without ribavirin in HCV genotype-1 prior null-responder/treatment-naïve patients (COSMOS study): primary endpoint (SVR12) results in patients with METAVIR F3-4 (Cohort 2). 49th Annual Meeting of EASL. London, UK, April 9-13, 2014.
84. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-64.
85. Jacobson I, Gordon S, Kowdley K, Yoshida E, Rodriguez Torres M, Sulkowski M. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. New Engl J Med 2013; 368: 1867-77.
86. Zeuzem S, Dusheiko G, Salupere R, Mangia A, Flisiak R, Hyland R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. New Engl J Med 2014; 370: 1993-2001.
87. Pawlotsky JM. NS5A inhibitors in the treatment of hepatitis C. J Hepatol 2013; 59 (2): 375-82.
88. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, Lawitz E, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370: 211-21.
89. Negro F, Alberti A. The global health burden of hepatitis C virus infection. Liver Int 2011; 31 (Suppl 2): 1-3.
90. Andriulli A, Dalgard O, Bjøro K, Mangia A. Short-term treatment duration for HCV-2 and HCV-3 infected patients. Dig Liver Dis 2006; 38: 741-8.
91. Marcellin P, Cheinquer H, Curescu M, Dusheiko GM, Ferenci P, Horban A, Jensen D, et al. High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. Hepatology (Baltimore, Md) 2012; 56: 2039-2050.
92. Bühler S, Bartenschlager R. New targets for antiviral therapy of chronic hepatitis C. Liver Int 2012; 32 (Suppl 1): 9-16.
93. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011; 364: 1195-206.
94. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011; 364: 2405-16.
95. Foster GR, Hézode C, Bronowicki JP, Carosi G, Weiland O, Verlinden L, van Heeswijk R, et al. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 2011; 141: 881-889. e1.
96. Silva MO, Treitel M, Graham DJ, Curry S, Frontera MJ, McMonagle P, Gupta S, et al. Antiviral activity of boce previr monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3. J Hepatol 2013; 59: 31-7.
97. Dore GJ, Lawitz E, Hezode C, Shafran S, Ramji A, Tatum H. Daclatasvir combined with peginterferon alfa-2a and ribavirin for 12 or 16 weeks in patients with hepatitis C virus genotype 2 or 3 infection: COMMAND GT 2/3 Study. J Hepatol 2013; 58 (Suppl 1): S570.
98. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, Hindes RG, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368: 34-44.
99. Lawitz E, Lalezari JP, Hassanein T, Kowdley KV, Poordad FF, Sheikh AM, Afdhal NH, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. The Lancet Infectious Diseases 2013.
100. Lawitz E, Poordad F, Brainard D, Hyland RH, An D, Symonds WT. Sofosbuvir in combination with PegIFN and ribavirin for 12 weeks provides high SVR rates in HCV-infected genotype 2 or 3 treatment-experienced patients with and without compensated cirrhosis: results from the LONESTAR-2 study. Hepatology (Baltimore, Md). 2013; 58: (Supl 1) 1380A.
101. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, et al. Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection. N Engl J Med. 2013; 368: 1878-1887.
102. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-77.
103. Esteban R, Nyberg L, Lalezan J, Ni L, Doehle B, Kanwar B, et al. Successful retreatment with sofosbuvir-containing regimens for HCV genotype 2 or 3 infected patients who failed prior sofosbuvir plus ribavirin therapy. J Hepatol 2014; 60 (Suppl 1): S4.
104. Gane EJ, Hyland RH, An D, Pang PS, Symonds WT, Mchutchison JG, et al. Sofosbuvir/ledipasvir fixed dose combination is safe and effective in difficult-to-treat populations including genotype-3 patients, decompensated genotype-1 patients, and genotype-1 patients with prior sofosbuvir treatment experience. J Hepatol 2014; 60 (Suppl 1): S3.
105. Everson GT, Tran TT, Towner WJ, Davis MN, Wyles D, Nahass R, et al. Safety and efficacy of treatment with the interferon-free, ribavirin-free combination of sofosbuvir + GS-5816 for 12 weeks in the treatment naive patients with genotype 1-6 HCV infection. J Hepatol 2014; 60 (Suppl 1): S46.
106. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, Lawitz E, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370: 211-221.
107. Verbeeck J, Maes P, Lemey P, Pybus OG, Wollants E, Song E, Nevens F, et al. Investigating the origin and spread of hepatitis C virus genotype 5a. J Virology 2006; 80 (9): 4220-6.
108. Blackard JT, Shata MT, Shire NJ, Sherman KE. Acute hepatitis C virus infection: a chronic problem. Hepatology. 2008; 47: 321-31.
109. Williams I. Epidemiology of hepatitis C in the United States. Am J Med 1999; 107: 2S.
110. Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000; 31: 777.
111. Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology 1997; 26: 15S.
112. Farci P, Alter HJ, Wong D, Miller RH, Shih JW, Jett B, Purcell RH, et al. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med 1991; 325: 98.
113. Wang TY, Kuo HT, Chen LC, Chen YT, Lin CN, Lee MM. Use of polymerase chain reaction for early detection and management of hepatitis C virus Ann Clin Lab Sci. 2002 Spring; 32: 137-41.
114. Maheshwari A, Thuluvath PJ. Management of acute hepatitis C. Clin Liver Dis 2010; 14: 169.
115. Beld M, Penning M, van Putten M, et al. Low levels of hepatitis C virus RNA in serum, plasma, and peripheral blood mononuclear cells of injecting drug users during long antibody-undetectable periods before seroconversion. Blood 1999; 94: 1183.
116. Wiese M, Grüngreiff K, Güthoff W, Lafrenz M, Oesen U, Porst H, et al. Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany-a 25-year multicenter study. J Hepatol 2005; 43: 59.
117. Nikolaeva LI, Blokhina NP, Tsurikova NN, Voronkova NV, Miminoshvili MI, Braginsky DM, Yastrebova ON, et al. Virus-especific antibody titres in different phases of hepatitis C virus infection. J Viral Hepat 2002; 9: 429.
118. Wawrzynowicz-Syczewska M, Kubicka J, Lewandowski Z, Borol-Kaczmarska A, Radkowski M, et al. Natural history of acute symptomatic hepatitis type C. Infection 2004; 32: 138.
119. Loomba R, Rivera MM, McBurney R, Park Y, Haynes-Williams V, Rehermann B, Alter HJ, et al. The natural history of acute hepatitis C: clinical presentation, laboratory findings and treatment outcomes. Aliment Pharmacol Ther 2011; 33: 559.
120. Deterding K, Wiegand J, Grüner N, Hahn A, Jäckel E, Jung MC, Buggisch P, et al. The German Hep-Net acute hepatitis C cohort: impact of viral and host factors on the initial presentation of acute hepatitis C virus infection. Z Gastroenterol 2009; 47: 531.
121. Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung MC, Ulsenheimer A, Schraut WW, et al. Acute Hepatitis: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003; 125: 80.
122. Santantonio T, Sinisi E, Guastadisegni A, Casalino C, Mazzola M, Gentile A, Leandro G, et al. Natural course of acute hepatitis C: a long-term prospective study. Dig Liver Dis 2003; 35: 104.
123. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999; 340: 1228.
124. Missale G, Bertoni R, Lamonaca V, Valli A, Massari M, Mori C, Rumi MG, et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 1996; 98: 706.
125. Diepolder HM, Zachoval R, Hoffmann RM, Wierenga EA, Santantonio T, Jung MC, Eichenlaub D, et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995; 346: 1006.
126. Hofer H, Watkins-Riedel T, Janata O, Penner E, Holzmann H, Steindl-Munda P, Gangl A, Ferenci P. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology 2003; 37: 60.
127. Wiese M, Berr F, Lafrenz M, Porst H, Oesen U. Low frequency of cirrhosis in a hepatitis C (genotype 1b) singlesource outbreak in germany: a 20-year multicenter study. Hepatology 2000; 32: 91.
128. Rodger AJ, Roberts S, Lanigan A, Bowden S, Brown T, Crofts N. Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to1975. Hepatology 2000; 32: 582.
129. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, Nolt K, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000; 284: 450.
130. Villano SA, Vlahov D, Nelson KE, et al. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999; 29: 908.
131. Grebely J, Page K, Sacks-Davis R, van der Loeff MS, Rice TM, Bruneau J, Morris MD, et al. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology 2014; 59: 109.
132. Corey KE, Mendez-Navarro J, Gorospe EC, Zheng H, Chung RT, et al. Early treatment improves outcomes in acute hepatitis C virus infection: a meta-analysis. J Viral Hepat 2010; 17: 201.
133. Dore GJ, Hellard M, Matthews GV, Grebely J, Haber PS, Petoumenos K, Yeung B, et al. Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology 2010; 138: 123.
134. Broers B, Helbling B, François A, Schmid P, Chuard C, Hadengue A, Negro F. Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C. J Hepatol 2005; 42: 323.
135. Deterding K, Grüner N, Buggisch P, Wiegand J, Galle PR, Spengler U, Hinrichsen H, et al. Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. Lancet Infect Dis 2013; 13: 497.
136. Licata A, Di Bona D, Schepis F, Shahied L, Craxí A, Cammà C, et al. When and how to treat acute hepatitis C? J Hepatol 2003; 39: 1056.
137. Corey KE, Ross AS, Wurcel A, Schulze Zur Wiesch J, Kim AY, Lauer GM, Chung RT, et al. Outcomes and treatment of acute hepatitis C virus infection in United States population. Clin Gastroenterol Hepatol 2006; 4: 1278.
138. Kamal SM, Fouly AE, Kamel RR, Hockenjos B, Al Tawil A, Khalifa KE, He Q, et al. Peginterferon alpha-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology 2006; 130: 632.
139. Wiegand J, Buggisch P, Boecher W, Zeuzem S, Gelbmann CM, Berg T, Kauffmann W, et al. Early monotherapy with pegylated interferon alpha-2b of acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology 2006; 43: 250.
140. Santantonio T, Fasano M, Sinisi E, Guastadisegni A, Casalino C, Mazzola M, Francavilla R, et al. Efficacy of a 24-week course of PEG-IFN alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J Hepatol 2005; 42: 329.
141. Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, Pastore G, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001; 345: 1452.
142. Nunnari G, Montineri A, Portelli V, Savalli F, Fatuzzo F, Cacopardo B. The use of peginterferon in monotherapy or in combination with ribavirin for the treatment of acute hepatitis C. Eur Rev Med Pharmacol Sci 2012; 16: 1013.
143. Kamal SM, Ismail A, Graham CS, He Q, Rasenack JW, Peters T, Tawil AA, et al. Pegylated interferon alpha therapy in acute hepatitis C: realtion to hepatitis C virus-specific T cell response kinetics. Hepatology 2004; 39: 1721.
144. Serpaggi J, Chaix ML, Batisse D, Dupont C, Vallet-Pichard A, Fontaine H, Viard JP. et al. Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy. AIDS 2006; 20: 233.
145. Danta M, Dusheiko GM. Acute HCV in HIV-positive individuals-a review. Curr Pharm Des 2008; 14: 1690.
146. Laguno M, Martínez-Rebollar M, Perez I, Costa J, Larrousse M, Calvo M, Loncá M, et al. Low rate of sustained virological response in an outbreak of acute hepatitis C in HIV-infected patients. AIDS Res Hum Retrov 2012; 28: 1294.
147. Matthews GV, Hellard M, Haber P, Yeung B, Marks P, Baker D, McCaughan G, et al. Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trail in Acute Hepatitis C. Clin Infect Dis 2009; 48: 650.
148. Dominguez S, Ghosn J, Valantin MA, Schruniger A, Simon A, Bonnard P, Caumes E, et al. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients. AIDS 2006; 20: 1157.
149. Piroth L, Larsen C, Binquet C, Alric L, Auperin I, Chaix ML, Dominguez S, et al. Treatment of acute hepatitis C in human immunodeficiency virus-infected patients: the HEPAIG study. Hepatology 2010; 52: 1915.
150. Fierer DS, Dieterich DT, Mullen MP, Branch AD, Uriel AJ, Carriero DC, van Seggelen WO, et al. Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men. Clin Infect Dis 2014; 58: 873.
151. Kamal SM, Moustafa KN, Chen J, Fehr J, Abdel Moneim A, Khalifa KE, El Gohary LA, et al. Duration of peginterferon therapy in acute hepatitis C: a randomized trial. Hepatology 2006; 43: 923.
152. Hézode C, Fontaine H, Dorival C, Zoulim F, Larrey D, Canva V, De Ledinghen V, et al. CUPIC Study Group. Effectiveness of telaprevir or boceprevir in treatmentexperienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology 2014; 147: 132-142.
153. Saxena V, Manos MM, Yee HS, Catalli L, Wayne E, Murphy RC, Shvachko VA, et al. Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis. Aliment Pharmacol Ther. 2014; 39: 1213-24.
154. Latin American Association for the Study of the Liver Practice Guidelines. Diagnosis, management, and treatment of hepatitis C. Ann Hepatol 2010; 9 (Suppl): 8-26.
155. Jacobson IM, Dore GJ, Foster G, et al. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype-1 infection in treatment-naïve patients: results from QUEST-1, a phase III trial. Digestive Disease Week, May 18-21, 2013; Orlando, FL.
156. Poordad F, Manns MP, Marcellin P, et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naïve patients: results from QUEST-2, a phase III trial. Digestive Disease Week, May 18-21, 2013; Orlando, FL.
157. Pessôa MG, Mazo DF, De Carvalho IMVG, Carrilho FJ. (Resistant associated variants to protease inhibitors in Brazil) Mutações de resistência aos inibidores de protease no Brasil. Review article. Rev Panam Infectol 2014; 16(1): 57-61.
158. Forns X, Lawitz E, Zeuzem S, et al. Simeprevir (TMC435) with peg-interferon a-2a/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: efficacy and safety in patient sub-populations in the PROMISE phase III trial. 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2013). Nov 1-5, 2013, 2013b; Washington, DC.
159. Jacobson IM, Ghalib RH, Rodriguez-Torres M, et al. SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatmentnai? ve and prior null responder patients: the COSMOS study. Hepatology: special issue: The 64th Annual Meeting of the American Association for the Study of Liver Diseases: the Liver Meeting 2013. 2013; 58(4): 1379A.
160. Lawitz E, Poordad F, Membreno FE, et al. Once daily sofosbuvir/ledipasvir fixed dose combination with or without ribavirin resulted in?95% sustained virologic response in patients with HCV genotype 1, including patients with cirrhosis: the LONESTAR trial. Program and abstracts of the 64th Annual Meeting of the American Association for the Study of Liver Diseases; November 1-5, 2013; Washington, DC. 215A.
161. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. et al. The association between hepatitis C infection and survival after orthotopic liver Transplantation. Gastroenterology 2002; 122: 889-96.
162. Garcia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M, Rimola A, et al. Hepatitis C virus kinetics during and immediately after liver Transplantation. Hepatology 2002; 35: 680-7.
163. Peng CY, Chien RN, Liaw YF. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J Hepatol 2012; 57(2): 442-50.
164. Forns X, García-Retortillo M, Serrano T, Feliu A, Suarez F, de la Mata M, García-Valdecasas JC, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver Transplantation. J Hepatol 2003; 39(3): 389-96.
165. Carrión JA, Martínez-Bauer E, Crespo G, Ramírez S, Pérez-del-Pulgar S, García-Valdecasas JC, Navasa M, et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver Transplantation: a retrospective study. J Hepatol 2009; 50(4): 719-28.
166. Everson GT, Terrault NA, Lok AS, et al. Adult-to-adult living donor liver Transplantation cohort study. A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver Transplantation. Hepatology 2013; 57(5): 1752-62.
167. Fontaine H, Hezode C, Dorival C, et al. SVR12 rates and safety of triple therapy including telaprevir or boceprevir in 221 cirrhotic non-responders treated in the French Early Access Program (ANRSCO20-CUPIC). J Hepatol 2013; 58: S27.
168. Hézode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, de Ledinghen V, et al. CUPIC study group. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRSCO20-CUPIC)-NCT01514890. J Hepatol 2013; 59(3): 434-41.
169. Verna EC, Terry N, Lukose T, et al. High early response rates with protease inhibitor triple therapy in a multicenter cohort of HCV infected patients awaiting liver Transplantation. Hepatology 2012; 56(Suppl 1): 218A.
170. Curry MP, Forns X, Chung RT, et al. Pretransplant sofosbuvir and ribavirin to prevent recurrence of HCV infection after liver Transplantation. Hepatology 2013; 58 (Suppl 1): 314A.
171. Lens S, Gambato M, Londoño MC, Forns X. Interferonfree regimens in the liver-transplant setting. Semin Liver Dis 2014; 34: 58-71.
172. Charlton M, Ruppert K, Belle SH, et al. Long-term results and modeling to predict outcomes in recipients with HCV infection: results of the NIDDK liver Transplantation database. Liver Transpl 2004; 10: 1120-30.
173. Berenguer M, Prieto M, Rayón JM, Mora J, Pastor M, Ortiz V, Carrasco D, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver Transplantation. Hepatology 2000; 1: 852-8.
174. Gane EJ. The natural history of recurrent hepatitis C and what influences this. Liver Transpl 2008; 14 (Suppl 2): S36-44.
175. Berenguer M, Mccaughan G. Hepatitis C virus-associated cholestatic hepatitis: we cannot seem to agree on diagnostic criteria. Liver Transpl 2013; 19: 115-7.
176. Roche B, Sebagh M, Canfora ML, Antonini T, Roque-Afonso AM, Delvart V, Saliba F, et al. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl 2008; 14: 1766-77.
177. Mazzaferro V, Tagger A, Schiavo M, Regalia E, Pulvirenti A, Ribero ML, Coppa J, et al. Prevention of recurrent hepatitis C after liver Transplantation with early interferon and ribavirin treatment. Transplant Proc 2001; 33: 1355-7.
178. Chalasani N, Manzarbeitia C, Ferenci P, Vogel W, Fontana RJ, Voigt M, Riely C, et al. Peginterferon alpha-2a for hepatitis C after liver Transplantation: 2 randomized, controlled trials. Hepatology 2005; 41: 289-98.
179. Bzowej N, Nelson DR, Terrault NA, Everson GT, Teng LL, Prabhakar A, Charlton MR. PHOENIX: a randomized controlled trial of peginterferon alpha-2a plus ribavirin as a prophylactic treatment after liver Transplantation for hepatitis C virus. Liver Transpl 2011; 17: 528-38.
180. Shergill AK, Khalili M, Straley S, Bollinger K, Roberts JP, Ascher NA, Terrault NA, et al. Applicability, tolera bility and efficacy of preemptive antiviral therapy in hepatitis Cinfected patients undergoing liver Transplantation. Am J Transplant 2005; 5: 118-24.
181. Sugawara Y, Makuuchi M, Matsui Y, Kishi Y, Akamatsu N, Kaneko J, Kokudo N, et al. Preemptive therapy for hepatitis C virus after living-donor liver Transplantation. Transplantation 2004; 78: 1308-11.
182. Carrión JA, Torres F, Crespo G, Miquel R, García-Valdecasas JC, Navasa M, Forns X. Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver Transplantation. Hepatology 2010; 51: 23-34.
183. Blasco A, Forns X, Carrión JA, García-Pagán JC, Gilabert R, Rimola A, Miquel R, et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver Transplantation. Hepatology 2006; 43: 492-9.
184. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008; 49: 274-87.
185. Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K. Interferon-based combination anti-viral therapy for hepatitis C virus after liver Transplantation: a review and quantitative analysis. Am J Transplant 2006; 6: 1586-99.
186. Xirouchakis E, Triantos C, Manousou P, Sigalas A, Calvaruso V, Corbani A, Leandro G, et al. Pegylated interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and metaanalysis of prospective controlled studies. J Viral Hepat 2008; 15: 699-709.
187. Coilly A, Roche B, Dumortier J, et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver Transplantation, a multicenter experience. J Hepatol 2013; doi: 10. 1016/j. jhep. 2013. 08. 018. (in press).
188. Pungpapong S, Aqel BA, Koning L, Murphy JL, Henry TM, Ryland KL, Yataco ML, et al. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver Transplantation. Liver Transpl 2013; 19: 690-700.
189. Werner CR, Egetemeyr DP, Lauer UM, Nadalin S, Königsrainer A, Malek NP, Berg CP, et al. Telaprevir based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data. Liver Transpl 2012; 18: 1464-70.
190. Samuel D, Charlton M, Gane E, et al. Sofosbuvir and ribavirin for the treatment of recurrent hepatitis C infection after liver Transplantation: results of a prospective, multicenter study. 49th European Association for the Study of the Liver International Liver Congress (EASL 2014). London, April 9-13, 2014. Abstract, P1232.
191. Fontana RJ, Hughes EA, Bifano M, Appelman H, Dimitrova D, Hindes R, Symonds WT. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant 2013; 13: 1601-5.
192. Hernandez MD, Sherman KE. HIV/hepatitis C coinfection natural history and disease progression. Curr Opin HIV AIDS 2011; 6(6): 478-82.
193. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, Koziel MJ. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 15, 33 (4): 562-9.
194. European AIDS Clinical Society. Guidelines, version 7. 0. October 2013. http://www. eacsociety. org/Portals/0/Guidelines_Online_131014. pdf (Accessed on May 25, 2014).
195. Macías J, Márquez M, Merino D, et al. Short-term risk of decompensation among HIV/HCV-coinfected patients with significant fibrosis. 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014). Boston, March 3-6. Abstract 646.
196. Mendes-Corrêa M, Núñez M. Management of HIV and hepatitis virus coinfection. Expert Opin Pharmacother 2010; 11(15): 2497-516.
197. Telaprevir prescription information: access June 2014. h t t p://w w w. j a n s s e n. c o m. a u/f i l e s/P r o d u c t s/Incivo_PI. pdf?ac941bb8343879d4b017c876e58d73aa.
198. Boceprevir prescription information: access June 2014. http://www. merck. com/product/usa/pi_circulars/v/victrelis/victrelis_pi. pdf.
199. Dieterich D, Rockstroh J, Orkin C, et al. Simeprevir (TMC435) plus peg-IFN/ribavirin in HCV genotype-1/HIV-1 coinfection (Study C212). 21st Conference on retroviruses and opportunistic infections, March 3-6, 2014; abstract 24.
200. Simeprevir prescription information: access june 2014.
201. Rodriguez-Torres M, Rodriguez-Orengo J, Gaggar A, et al. Sofosbuvir and peginterferon alpha-2a/ribavirin for treatment-naïve genotype 1-4 HCV infected patients who are HIV coinfected with HIV. ID Week 2013; abstract 714.
202. Lawitz E, et al. Simeprevir plus sofosbuvir with/without ribavirin in HCV genotype 1 prior null-responder/treatment-naïve patients (COSMOS study): primary endpoint (SVR12) results in patients with Metavir F3-4 (cohort 2). 49th EASL. Abstract 165.
203. Naggie S, Sulkowski M, Lalezari J, et al. Sofosbuvir plus ribavirin for HCV genotype 1-3 infection in HIV coinfected patients (PHOTON-1). CROI 2014. Conference on retroviruses and opportunistic infections. Abstract 26.
204. Lacombe K, Valin N, Stitou H, Gozlan J, Thibault V, Boyd A, Poirier JM, et al. Efficacy and tolerance of telaprevir in HIV-hepatitis C virus genotype 1-coinfected patients failing previous antihepatitis C virus therapy: 24-week results. AIDS 2013; 27(8): 1356-9.
205. Cachay ER, Wyles DL, Torriani FJ, Ballard C, Colwell B, Lin JC, et al. High incidence of serious adverse events in HIV-infected patients treated with a telaprevir-based hepatitis C virus treatment regimen. AIDS 2013; 27: 000-000. AIDS. 2013 Jul 24. [Epub ahead of print] PMID: 23842130.
206. Genebat M, Vera F, Hernández-Quero J, Domingo P, Guardiola JM, Martínez-Madrid O, Martínez L, et al. Efficacy and tolerability after 24 weeks of treatment with telaprevir, pegylated interferon and ribavirin in cirrhotic HIV-HCV coinfected subjects. Antiviral Res 2014; 104: 59-61.
207. Martel-Laferrière V, Brinkley S, Bichoupan K, Posner S, Stivala A, Perumalswami P, Schiano T, et al. Virological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfection. HIV Med 2014; 15(2): 108-15.
208. http://www. hep-druginteractions. org/.
209. Sofosbuvir prescription information: access June 2014. http://www. gilead. com/~/media/Files/pdfs/medicines/liver disease/sovaldi/sovaldi_pi. pdf.
210. Zarski JP, Bohn B, Bastie A, Pawlotsky JM, Baud M, Bost-Bezeaux F, Tran van Nhieu J, et al. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol 1998; 28: 27-33.
211. Chen DS, Kuo GC, Sung JL, Lai MY, Sheu JC, Chen PJ, Yang PM, et al. Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience. J Infect Dis 1990; 162(4): 817-22.
212. Pallas JR, Farinas-Alvarez C, Prieto D, Delgado-Rodríguez M. Co-infections by HIV, hepatitis B and hepatitis C in imprisoned injecting drug users. Eur J Epidemiol 1999; 15: 699-704.
213. Gentile I, Di Flumeri G, Scarica S, Frangiosa A, Foggia M, Reynaud L, Borgia G, et al. Acute hepatitis C in patients undergoing hemodialysis: experience with highdose interferon therapy. Minerva Urol Nefrol 2013; 65: 83-4.
214. Zhou J, Dore GJ, Zhang F, Lim PL, Chen YM. TREAT Asia HIV Observational Database. Hepatitis B and C virus coinfection in the TREAT Asia HIV observational database. J Gastroenterol Hepatol 2007; 22: 1510-8.
215. Mimms LT, Mosley JW, Hollinger FB, Aach RD, Stevens CE, Cunningham M, Vallari DV. Effect of concurrent acute infection with hepatitis C virus on acute hepatitis B virus infection. BMJ 1993; 307: 1095-7.
216. Yan BM, Lee SS. Acute coinfection with hepatitis B and hepatitis C viruses. Can J Gastroenterol 2005; 19(12): 729-30.
217. Sagnelli E, Coppola N, Pisaturo M, Masiello A, Tonziello G, Sagnelli C, Messina V. HBV superinfection in HCV chronic carriers: a disease that is frequently severe but associated with the eradication of HCV. Hepatology 2009; 49(4): 1090-7.
218. Potthoff A, Wedemeyer H, Boecher WO, Berg T, Zeuzem S, Arnold J, Spengler U, et al. Hep-Net B/C co-infection study group. The Hep-Net B/C co-infection trial: a prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with with HBV/HCV co-infection. J Hepatol 2008; 49(5): 688-94.
219. Raimondo G, Brunetto MR, Pontisso P, Smedile A, Maina AM, Saitta C, Squadrito G, et al. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients. Hepatology 2006; 43: 100-7.
220. Brass V, Moradpour D. New insights into hepatitis B and C virus co-infection. J Hepatol 2009; 51(3): 423-5.
221. Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: 2012 update. Hepatol Int 2012; 6: 531-61.
222. Gadano A, Daruich J, Cheinquer H, Faimboin H, Pessoa M, Tanno H, Mattos A, et al. Latin American guideline for the management of chronic hepatitis B. Acta Gastroenterol Latinoam 2011; 41(4): 340-50.
223. Villa E, Grottola A, Buttafoco P, Colantoni A, Bagni A, Ferretti I, Cremonini C, et al. High doses of alpha-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: long term results of a prospective randomized trial Am J Gastroenterol. 2001; 96: 2973-7.
224. Liu CJ, Chuang WL, Lee CM, et al. An open label, comparative, multicenter study of peginterferon alpha-2a plus ribavirin in the treatment of patients with chronic hepatitis C/hepatitis B co-infection versus those with chronic hepatitis C monoinfection. Gastroenterology 2009; 136: 496-504.
225. Liu CJ, Chu YT, Shau WY, Kuo RN, Chen PJ, Lai MS. Treatment of patients with dual hepatitis C and B by peginterferon alpha and ribavirin reduced risk of hepatocellular carcinoma and mortality. Gut 2014; 63(3): 506-14.
226. Yu ML, Lee CM, Chen CL, Chuang WL, Lu SN, Liu CH, Wu SS, et al. Sustained HCV clearance and increased HBsAg seroclearance in patients with dual chronic hepatitis C and B during post-treatment follow-up. Hepatology 2013; 57: 2135-42.
227. Sagnelli E, Pisaturo M, Martini S, Sagnelli C, Filippini P, Coppola N, et al. Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection. Expert Opin Pharmacother 2014; 15(10): 1337-49.
228. Yu ML, Lee CM, Chuang WL, Lu SN, Dai CY, Huang JF, Lin ZY, et al. HBsAg profiles in patients receiving peginterferon alpha-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. J Infect Dis 2010; 202(1): 86-92.
229. Yu JW, Sun LJ, Zhao YH, Kang P, Gao J, Li SC. Analysis of the efficacy of treatment with peginterferon alpha-2a and ribavirin in patients coinfected with hepatitis B virus and hepatitis C virus. Liver Int 2009; 29(10): 1485-93.
230. Bergman S, Accortt N, Turner A, Glaze J. Hepatitis C infection is acquired pre-ESRD. Am J Kidney Dis 2005; 45: 684-9.
231. Ilcöl B, Ozener C, Avsar M IIcol Y, Lawrence R, Ozer A, Cirakoglu B, Akoglu E. Hepatitis C infection in patients with chronic renal failure receiving conservative therapy [letter]. Nephrol Dial Transplant 1997; 12: 626.
232. Kumar H, Naqvi SA, Ahmed A, Hamid S. Hepatitis-C virus antibodies (anti-HCV) in haemodialyzed vs non-dialyzed patients. J Pak Med Assoc 1994; 44: 28-30.
233. Fabrizi F, Marcelli D, Bacchini G, Guarnori I, Erba G, Locatelli F. Antibodies to hepatitis C virus (HCV) in chronic renal failure (CRF) patients on conservative therapy: prevalence, risk factors and relationship to liver disease. Nephrol Dial Transplant 1994; 9: 780.
234. Lemos LB, Perez RM, Lemos MM, Draibe SA, Silva IS, Silva AE, Ferraz ML. Hepatitis C among predialysis patients: prevalence and characteristics in a large cohort of patients. Nephron Clin Pract 2008; 108(2): c135-40.
235. Lemos LB, Perez RM, Lemos MM, Lanzoni VP, Draibe SA, Silva IS, Silva AE, et al. Hepatitis C in chronic kidney disease: predialysis patients present more severe histological liver injury than hemodialysis patients? Am J Nephrol 2007; 27(2): 191-6.
236. Martin P, Carter D, Fabrizi F, Dixit V, Conrad AJ, Artinian L, Peacock V, et al. Histopathological features of hepatitis C in renal transplant candidates. Transplantation 2000; 69: 1479-84.
237. National Kidney Foundation, 2002. KDOQI clinical practice guidelines for chronic kidney disease.
238. Liu CH, Huang CF, Liu CJ, Dai CY, Liang CC, Huang JF, Hung PH, et al. Pegylated interferon-alpha2a with or without low-dose ribavirin for treatment-naïve patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Ann Intern Med 2013; 159: 729-38.
239. Bassu PP, Siriki R, Shah NJ, et al. Telaprevir with adjusted dose of ribavirin in naïve CHC-G1: efficacy and treatment in CHC in hemodialysis population. Target C (RCT). J Hepatol 2013: 58: S301-S31.
240. Treitel M, Marbury T, Preston RA, et al. Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function. Clin Pharmacokinet 2012; 51: 619-28.
241. Van Heeswijk R, Vandevoorde A, Boogaerts G, et al. The effect of severe renal impairment on the pharmacokinetics of the investigational HCV protease inhibitor telaprevir. J Hepatol 2011; 54: S492.
242. De Kanter CT, Drenth JP, Arends JE, Reesink HW, van der Valk M, de Knegt RJ, Burger DM. Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet 2014; 53(5): 409-27.
243. Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial 2005; 18: 52-61.
244. Othman B, Monem F. Prevalence of antibodies to hepatitis C virus among hemodialysis patients in Damascus, Syria. Infection 2001; 29: 262-5.
245. Abbott KC, Bucci JR, Matsumoto CS, Swanson SJ, Agodoa LY, Holtzmuller KC, Cruess DF, et al. Hepatitis C and renal Transplantation in the era of modern immunosuppression. J Am Soc Nephrol 2003; 14: 2908-18.
246. De Jesus Rodrigues de Freitas M, Fecury AA, de Almeida MK, Freitas AS, de Souza Guimaraes V, da Silva AM, da Costa RA, et al. Prevalence of hepatitis C virus infection and genotypes in patient with chronic kidney disease undergoing hemodialysis. J Med Virol 2013; 85: 1741-5.
247. Mendez-Sanchez N, Motola-Kuba D, Chavez-Tapia NC, Bahena J, Correa-Rotter R, Uribe M. Prevalence of hepatitis C virus infection among hemodialysis patients at a tertiary-care hospital in Mexico City, Mexico. J Clin Microbiol 2004; 42: 4321-2.
248. Beltran M, Navas MC, De la Hoz F, Mercedes Munoz M, Jaramillo S, Estrada C, et al. Hepatitis C virus seroprevalence in multi-transfused patients in Colombia. J Clin Virol 2005; 34 (Suppl 2): S33-8.
249. Monsalve-Castillo F, Gomez-Gamboa L, Chacin-Bonilla L, Porto-Espinoza L, Costa-Leon L. Hepatitis C virus infection in hemodialysis patients in Maracaibo, Venezuela. Rev Inst Med Trop Sao Paulo 2012; 54: 53-5.
250. Curciarello JO, Adrover RE, Chiera AO, Touceda LA, Giammona AM, Raimondi JC, Fassi JC. Hepatitis C viruses antibodies. Prevalence and their influence on morbidity-mortality in renal transplant recipients, in the last two years of the kidney Transplantation program in La Plata city. Acta Gastroenterol Latinoam 1996; 26: 79-83.
251. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Meta-analysis: effect of hepatitis C virus infection on mortality in dialysis. Aliment Pharmacol Ther 2004; 20: 1271-7.
252. Zylberberg H, Nalpas B, Carnot F, Skhiri H, Fontaine H, Legendre C, Kreis H, et al. Severe evolution of chronic hepatitis C in renal Transplantation: a case control study. Nephrol Dial Transplant 2002; 17: 129-33.
253. Okoh EJ, Bucci JR, Simon JF, Harrison SA. HCV in patients with end-stage renal disease. Am J Gastroenterol 2008; 103: 2123-34.
254. Baid-Agrawal S, Pascual M, Moradpour D, Frei U, Tolkoff-Rubin N. Hepatitis C virus infection in haemodialysis and kidney transplant patients. Rev Med Virol 2008; 18: 97-115.
255. KDIGO. Kidney disease: improving global O. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl 2008; 109: S1-99.
256. Terrault NA, Adey DB. The kidney transplant recipient with hepatitis C infection: pre-and post-Transplantation treatment. Clin J Am Soc Nephrol 2007; 2: 563-75.
257. Mikolasevic I, Racki S, Lukenda V, Milic S, Pavletic-Persic M, Orlic L. Nonalcoholic fatty liver disease in renal transplant recipients proven by transient elastography. Transplant Proc 2014; 46: 1347-52.
258. Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther 2003; 18: 1071-81.
259. Russo MW, Goldsweig CD, Jacobson IM, Brown RS, Jr. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am J Gastroenterol 2003; 98: 1610-5.
260. Bruchfeld A, Stahle L, Andersson J, Schvarcz R. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection-a pilot study. J Viral Hepat 2001; 8: 287-92.
261. Bruchfeld A, Lindahl K, Reichard O, Carlsson T, Schvarcz R. Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hepat 2006; 13: 316-21.
262. Tan AC, Brouwer JT, Glue P, van Leusen R, Kauffmann RH, Schalm SW, de Vries RA, et al. Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study. Nephrol Dial Transplant 2001; 16: 193-5.
263. Covic A, Maftei ID, Mardare NG, Ionita-Radu F, Totolici C, Tuta L, Golea O, et al. Analysis of safety and efficacy of pegylated-interferon alpha-2a in hepatitis C virus positive hemodialysis patients: results from a large, multicenter audit. J Nephrol 2006; 19: 794-801.
264. Gordon CE, Uhlig K, Lau J, Schmid CH, Levey AS, Wong JB. Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms. Am J Kidney Dis 2008; 51: 263-77.
265. Glue P. The clinical pharmacology of ribavirin. Semin Liver Dis 1999; 19 (Suppl 1): 17-24.
266. Dumortier J, Guillaud O, Gagnieu MC, Janbon B, Juillard L, Morelon E, Leroy V, et al. Anti-viral triple therapy with telaprevir in haemodialysed HCV patients: is it feasible? J Clin Virol 2013; 56: 146-9.
267. Donahue JG, Muñoz A, Ness PM, Brown DE Jr, Yawn DH, McAllister HA Jr, Reitz BA, et al. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med 1992; 327: 369-73.
268. Natov SN, Lau JY, Bouthot BA, Murthy BV, Ruthazer R, Schmid CH, Levey AS, et al. Serologic and virologic profiles of hepatitis C infection in renal transplant candidates. New England Organ Bank Hepatitis C Study Group. Am J Kidney Dis 1998; 31: 920-7.
269. Pereira BJ, Levey AS. Hepatitis C virus infection in dialysis and renal Transplantation. Kidney Int 1997; 51: 981-99.
270. Fissell RB, Bragg-Gresham JL, Woods JD, Jadoul M, Gillespie B, Hedderwick SA, Rayner HC, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int 2004; 65: 2335-42.
271. Jadoul M, Cornu C, van Ypersele de Strihou C. Incidence and risk factors for hepatitis C seroconversion in hemodialysis: a prospective study. The UCL Collaborative Group. Kidney Int 1993; 44: 1322-6.
272. Puro V, Petrosillo N, Ippolito G. Risk of hepatitis C seroconversion after occupational exposures in health care workers. Italian Study Group on Occupational Risk of HIV and Other Bloodborne Infections. Am J Infect Control 1995; 23: 273-7.
273. Brugnano R, Francisci D, Quintaliani G, Gaburri M, Nori G, Verdura C, Giombini L, et al. Antibodies against hepatitis C virus in hemodialysis patients in the central Italian region of Umbria: evaluation of some risk factors. Nephron 1992; 61: 263-5.
274. Centers for Disease C, prevention. Hepatitis C virus transmission at an outpatient hemodialysis unit-New York, 2001-2008. Morb Mortal Wkly Rep 2009; 58: 189-94.
275. Okuda K, Hayashi H, Kobayashi S, Irie Y. Mode of hepatitis C infection not associated with blood transfusion among chronic hemodialysis patients. J Hepatol 1995; 23: 28-31.
276. Gilli P, Moretti M, Soffritti S, Marchi N, Malacarne F, Bedani PL, De Paoli Vitali E, et al. Non-A, non-B hepatitis and anti-HCV antibodies in dialysis patients. Int J Artif Organs 1990; 13: 737-41.
277. Jadoul M, Cornu C, van Ypersele de Strihou C. Universal precautions prevent hepatitis C virus transmission: a 54 month follow-up of the Belgian Multicenter Study. The Universitaires Cliniques St-Luc (UCL) Collaborative Group. Kidney Int 1998; 53: 1022-5.
278. Summary of product characteristics, Victrelis 200 mg hard capsules [cited; Available from: http://www. medicines. org. uk/emc/medicine/24768/SPC/.
279. Ghosal A, Yuan Y, Tong W, Su AD, Gu C, Chowdhury SK, Kishnani NS, et al. Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor. Drug Metab Dispos 2011; 39: 510-21.
280. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alpha-2a or-2b to patients with chronic hepatitis C. Gastroenterology 2011; 140: 459-468 e1; quiz e14.
281. Buti M, Agarwal K, Horsmans Y. OPTIMIZE trial: non-inferiority of twice-daily telaprevir versus administration every 8 hours in treatment-naive, genotype 1 HCV infected patients. Hepatology 2012; 56: 91A-144A.
282. Van Heeswijk RP, Beumont M, Kauffman RS, Garg V. Review of drug interactions with telaprevir and antiretrovirals. Antivir Ther 2013; 18: 553-60.
283. Garg V, Chandorkar G, Farmer HF, Smith F, Alves K, van Heeswijk RP. Effect of telaprevir on the pharmacokinetics of midazolam and digoxin. J Clin Pharmacol 2012; 52: 1566-73.
284. Kiser JJ, Burton JR, Jr., Everson GT. Drug-drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol 2013; 10: 596-606.
285. VICTRELIS capsules, prescribing information [cited; Available from: http://www. merck. com/product/usa/pi_circulars/v/victrelis/victrelis_pi. pdf2013.
286. Summary of product characteristics, INCIVO 375 mg film coated tablets [cited; Available from: http://www. medicines. org. uk/EMC/medicine/25038/SPC/INCIVO+375+mg+film+coated+tablets/2012.
287. Back D, Else L. The importance of drug-drug interactions in the DAA era. Dig Liver Dis 2013; 45 (Suppl 5): S343-8.
288. Hulskotte EG, Feng HP, Xuan F, van Zutven MG, Treitel MA, Hughes EA, O'Mara E, et al. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology 2012; 56: 1622-30.
289. Garg V, Kauffman RS, Beaumont M, van Heeswijk RP. Telaprevir: pharmacokinetics and drug interactions. Antivir Ther 2012; 17: 1211-21.
290. Lee JE, van Heeswijk R, Alves K, Smith F, Garg V. Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin. Antimicrob Agents Chemother 2011; 55: 4569-74.
291. Hulskotte E, Gupta S, Xuan Y. Pharmoacokinetic evaluation of the interaction between the HCV protease inhibitor and the HMG-CoA reductase inhibitors atorvastatin and pravastatin, 16th Annual Meeting of HEP DART; 2011.
292. Zinego AL, Craxi A. Extrahepatic manifestations of hepatitis C virus infection. Clin Liver Dis 2008; 12: 611-36.
293. Ko HM, Hernandez-Prera JC, Zhu H, et al. Morphologic features of extrahepatic manifestation of hepatitis C virus infection. Clin Develop Immunes 2012; 740138: 1-9.
294. Iannuzzella F, Vaglio A, Garini G. Management of hepatitis C virus related mixed cryoglobulinemia. Am J Med 2010; 123: 400-8.
295. Saadoun D, Delluc A, Piette JC, Cacoub P. Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis. Curr Op Rheumatol 2008; 20(1): 23-8.
296. Ghosn SH, Kibbi AG. Cutaneous manifestations of liver diseases. Clin Dermatology 2008; 26: 274-82.
297. Fabrizi F, Lunghi G, Messa P. Therapy of hepatitis C virus-associated glomerulonephritis: current approaches. J Nephrol 2008: 21: 813-25.
298. Biasiotta A, Casato M, La Cesa S, Colantuono S, Di Stefano G, Leone C, Carlesimo M, et al. Clinical, neurophysiological, and skin biopsy findings in peripheral neuropathy associated with hepatitis C virus-related cryoglobulinemia. J Neurol 2014; 261: 725-31.
299. Caballes FR, Sendi H, Bonkovsky HL. Hepatitis C, porphyria cutanea tarda and liver iron: an update. Liver International 2012, 32 (6): 880-93.
300. Jadali Z. Dermatologic manifestations of hepatitis C infection and the effect of interferon therapy: a literature review. Arch Iran Med 2012; 15(1): 43-8.
301. Cunha KS, Manso AC, Cardoso AS, Paixão JB, Coelho HS, Torres SR. Prevalence of oral lichen planus in Brazilian patients with HCV infection. Oral Surg Med Pathol Radiol Endodontol 2005; 100(3): 330-3.
302. Calvaruso V, Craxi A. Immunological alterations in hepatitis C virus infection. World J Gastroenterol 2013; 19(47): 8916-23.
303. Zignego AL, Piluso A, Gianinni C. HBV and HCV chronic infection: autoimmune manifestations and lymphoproliferation. Autoimmunity Reviews 2008; 8: 107-11.
304. Dammacco F, Lauletta G, Montrone M, et al. Mixed cryoglobulinemia: a model of virus-related disease in internal medicine. Dig Liver Dis 2007, 39(suppl 1): 58-12.
305. Fabrizi F, Dixit V, Messa P. Antiviral therapy of symptomatic HCV-associated mixed cryoglobulinemia: metaanalysis of clinical studies. J Med Virol 2013; 85: 1019-27.
306. Saadoun D, Pereche Rigon M, Thibault V. Antiviral treatment for hepatitis C virus associated mixed cryoglobulinemia vasculitis: a long term follow up study. Arthr Rheum 2006; 54: 3696-706.
307. Saadoun D, Resche Rigon M, Thibault V, Longuet M, Pol S, Blanc F, Pialoux G, et al. Peg-IFN B/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24. Ann Rheum Dis 2014; 73: 831-7.
308. Cacoub P, Delluc A, Saadoun D, Landau DA, Sene D. Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand? Ann Rheum Dis 2008; 67(3): 283-7.
309. Visentini M, Ludovisi S, Petrarca A, Pulvirenti F, Zaramella M, Monti M, Conti V, et al. A phase II single arm multicenter study of low dose rituximab in patients with hepatitis Cvirus-related mixed cryoglobulinemia and severe liver disease. Autoimmun Rev 2011; 10 (11): 714-9.
310. Petrarca A, Rigacci L, Caini P, Colagrande S, Romagnoli P, Vizzutti F, Arena U, et al. Safety and efficacy of rituximab in patients with hepatitis c virus-related mixed cryoglobulinemia and severe liver disease. Blood 2010; 116(3): 335-42.
311. Dammacco F, Tucci FA, Lauletta G, Gatti P, De Re V, Conteduca V, Sansonno S, et al. Pegylated interferon-VV, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood 2010; 116: 343-53.
312. Saadoun D, Resche Rigon M, Sene D, Terrier B, Karras A, Perard L, Schoindre Y, et al. Rituximab plus Peg-interferon-P/ribavirin compared with Peg-interferon-e/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood 2010; 116: 326-34.
313. Cacoub P, Terrier B, Saadoun D. Hepatitis C virus mixed cryoglobulinemia vasculitis: therapy options. Pres Med 2013; 84(4): 523-7.
314. Terrier B, Cacoub P. Cryoglobulinemia vasculitis: an update. Curr Op Rheumatol 2013; 25: 10-84.
315. Terrier B, Semoun O, Saadoun D, Sène D, Resche-Rigon M, Cacoub P. Prognostic factors in patients with hepatitis C virus infection and systemic vasculitis. Arthritis Rheum 2011; 63(6): 1748-57.